What is most rewarding?
With a focus on the business side of diagnostics I get most excited about the outcomes. Our tests are covered by many health plans, giving patients access to answers while avoiding surgeries. That means that patients, as a result of our work, have a clear path forward. We are making a real difference.
Real People,
Real Science,
Real Answers.
CHRISTOPHER HALL
President and Chief Operating Officer
Veracyte
This is the Age of Evidence.
Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek.

Veracyte gives patients a clearer path for the future.

We are leading in the Age of Evidence.
our impact
The Age
of Evidence
Veracyte's genomic tests have the potential to save billions of dollars each year in unnecessary surgery costs.
Learn More >
Now Covered by Medicare
Genomic test is first to gain Medicare coverage for use in lung cancer screening and diagnosis.
learn more >
Evidence Equals Impact
Hear Veracyte CEO Bonnie Anderson discuss in a "Business Rockstars" interview how the company’s genomic tests are transforming patient care.

watch now >


latest news
news and updates
Jul 31, 2017
Veracyte Announces Second Quarter 2017 Financial Results

learn more >
Jul 31, 2017
Veracyte Announces Pivotal Clinical Validation Data for Afirma Genomic Sequencing Classifier Presented at World Congress on Thyroid Cancer

learn more >
Jul 26, 2017
Veracyte Announces Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer

learn more >